Kazuki Sueyoshi
Tomiki Sumiyoshi- Department of Preventive Intervention for Psychiatric Disorders, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan
Several domains of cognitive function, e.g., verbal memory, information processing, fluency, attention, and executive function are impaired in patients with schizophrenia. Cognitive impairments in schizophrenia have attracted interests as a treatment target, because they are considered to greatly affect functional outcome. Electrophysiological markers, including electroencephalogram (EEG), particularly, event-related potentials, have contributed to psychiatric research and clinical practice. In this review, we provide a summary of studies relating electrophysiological findings to cognitive performance in schizophrenia. Electrophysiological indices may provide an objective marker of cognitive processes, contributing to the development of effective interventions to improve cognitive and social outcomes. Further efforts to understand biological mechanisms of cognitive disturbances, and develop effective therapeutics are warranted.
Introduction
Cognitive impairments are considered as a fundamental feature of schizophrenia (1). Patients with the illness present disturbances across several cognitive domains, such as executive function, some types of memory, attention, fluency, and information processing/speed (2, 3). Cognitive function predicts social function more accurately than psychotic symptoms, and has been drawing attention as target of treatment (4, 5).
The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) (6) and the Brief Assessment of Cognition in Schizophrenia (BACS) (7) have been developed to evaluate disturbances of cognitive function in schizophrenia. Also, as an interview-based multidimensional assessment tool of social function, the Specific Level of Functioning Scale (SLOF) has been implemented (8). In fact, social functioning, as measured by the SLOF, has been shown to be correlated with cognitive function, as measured by the BACS in patients with schizophrenia (9).
There is evidence for the role of electrophysiological measures as an objective marker of neuropsychological performance (10–13). In fact, electrophysiological responses generally precede behavior-based cognitive performances, and are also useful to predict treatment outcome regarding cognitive disturbances (10, 14, 15). This paper provides selective reviews of studies on the relationships among cognitive function, electrophysiological findings, and treatment response in patients with schizophrenia.
Electrophysiological Evidence in Schizophrenia
Spontaneous Electroencephalogram (EEG)
In general, functional neuroimaging techniques measuring blood flow and metabolism, such as functional magnetic resonance imaging (fMRI), positron emission tomography (PET), and Single photon emission computed tomography (SPECT) may not directly differentiate between activation and inhibition of a specific brain region (16). On the other hand, EEG consists of components of electrical activities that are inhibitory (e.g., slow “delta” frequencies), excitatory (e.g., fast “beta” frequencies) or steady-state (mid-range “theta” and “alpha” frequencies) in nature (16). Also, EEG has an advantage in terms of time resolution compared to other techniques to evaluate brain functions.
Imaging of electrophysiological activity, such as EEG, is feasible and cost-effective. For example, Pascual-Marqui et al. developed the low-resolution brain electromagnetic tomography (LORETA) (16), which is a source localization analytic estimator. The purpose of current source localization is to overcome the volume conductance problem in EEG analyses and cope with the reference confounding effects (16). Neuroleptic-naïve patients with first-episode schizophrenia have been reported to demonstrate hyperactivity of delta band in the frontal-prefrontal area and hypoactivity of middle range band (theta and alpha) in the left temporal parietal area by means of LORETA (16). These findings support the concept that cognitive disturbances of schizophrenia are generated by inhibition of frontal and left temporal areas (17).
Functional deviations of frontal lobes are reflected by disturbances of executive function and working memory in schizophrenia (18, 19). In fact, a meta-analysis of studies using fMRI and PET reports reduced activation in dorsolateral prefrontal cortex and anterior cingulate cortex during executive functioning task performance in patients with schizophrenia (18). The dysfunction related to auditory verbal hallucinations (20) is consistent with the role for the left temporal lobe in auditory perception and language processing (21, 22).
Inhibited activities of the left temporal area in schizophrenia are also demonstrated by using PET (23). Further, dysfunction of fronto-temporal connectivity has been reported in schizophrenia (24), consistent with Fletcher et al. suggesting the role for this anatomical complex in the psychopathology of schizophrenia (17). Accordingly, an fMRI study reported the relation of fronto-temporal connectivity with cognitive functions, including working memory (25). The reduction of blood flow and metabolism in the frontal and left temporal areas in schizophrenia was supported by Pascual-Marqui et al. (16) who found inhibition of electrical activities in these brain regions.
On the other hand, there is a report that mid-fast band frequencies were not altered in medicated-free patients with schizophrenia (26), although delta band activities were increased. In this line, an increase in the delta activity was noted in frontal areas, left inferior temporal gyrus, and parahippocampal gyrus of neuroleptic-naïve patients with schizophrenia, as revealed by LORETA (27).
Event-Related Potentials
Event-related potentials (ERPs) are linked in time with physical and mental events, and are typically extracted from the scalp-recorded EEG by means of signal averaging (28). ERP components, such as P50, mismatch negativity (MMN), and P300, provide neural activities associated with sensory-perceptual and cognitive events in the order of milli-seconds (29). P50 and MMN reflects attention-independent (pre-attentive) automatic information processes, while P300 has been used as a measure of attentive information processes (30).
P50 is a pre-attentional component recorded about 50 ms after the presentation of an auditory stimulus in the conditioning-testing paradigm. Its amplitude is suppressed when a second click sound is presented 500 ms after an initial click (31). The P50 suppression is thought to reflect a sensory gating mechanism aimed at protecting against information overload (32). A meta-analysis study has reported robust P50 suppression deficits in schizophrenia (33). Specifically, deficits of P50 suppression have been linked to poor performance on tests of cognitive domains, such as attention (34–36), working memory (11, 36), processing speed (11, 34), and executive function (35). These associations suggest that impaired P50 sensory gating provides a targets of interventions to alleviate cognitive disturbances of schizophrenia (11).
MMN is typically recorded in the condition where a subject is instructed to divert attention from stimuli generated by the auditory oddball task (37). MMN is generated when a stimulus violates the invariance or regularity of the recent auditory past. For example, MMN is recorded when an deviant stimulus that differs in frequency, duration, intensity, or location is presented among repeatedly presented standard stimuli (38). MMN is considered to provide an index of (1) auditory sensory or echoic memory, and (2) context-dependent information processing at the level of the primary and secondary auditory cortices (38). Parameters of MMN, e.g., amplitudes and latencies, are thought to reflect the first step in a chain of events leading to the conscious detection of differences between auditory stimuli and variance in the auditory environment (38).
Reduction of MMN amplitudes in patients with schizophrenia shows a large effect size as demonstrated by meta-analysis (38). Specifically, patients with chronic schizophrenia show a decrease in MMN current density in the right medial frontal gyrus, right cingulate gyrus, and right paracentral lobule (39). Altered MMN amplitudes have been associated with impairment of cognitive functions, such as attention (12, 40, 41), processing speed (41, 42), verbal learning (40, 43), verbal fluency (44), and executive function (42). Also, its amplitudes have been linked to functional outcomes (45–47). Overall, pre-attentive information processes serve as a gateway to higher cognitive and psychosocial functioning (12). Further, the ability of MMN to reflect functional outcomes have been reported to be better than those of behavior-based cognitive performances and social cognition (15). These considerations further support the utility of MMN as a marker of treatment effects on social functioning.
P300 is typically recorded when a subject is required to pay attention to infrequent stimuli in an auditory oddball task (48). Amplitudes of P300 waveforms, thought to reflect cognitive processes such as directed attention and the contextual updating of working memory (31), are reduced, and the latency of P300 are delayed in patient with schizophrenia (33). Altered P300 activities have been reported to correlate with clinical symptoms of schizophrenia (37). By means of LORETA, current sources of P300 were estimated to reside in the bilateral medial frontal and medial parietal cortex, bilateral superior temporal gyrus, right temporo-parietal junction, and left lateral prefrontal cortex (37).
P300 amplitudes have been shown to positively correlate with performance on tests of verbal learning (49), organization and discriminability of memory (13), attention (50), verbal fluency (49), and executive function (49). Also, prolonged latency of P300 has been associated with performance on tests of verbal learning (13) and verbal fluency (51). It is important that these domains of cognition are related with functional capacity and real-world functions (9, 52). Further, a correlation has been reported between P300 amplitudes and functional capacity (53). These considerations support the potential utility of P300 as a biomarker to predict treatment response (53).
Electrophysiological Changes During Treatment
Spontaneous EEG
Using above-mentioned electrophysiological markers, some studies have reported the effect of treatment on cognitive disturbances of schizophrenia. Repetitive transcranial magnetic stimulation produced the following changes in patients with schizophrenia (54); (1) an increase in delta band activities in bilateral anterior cingulate gyrus, (2) a decrease in beta-1 and beta-3 band in the middle temporal lobe ipsilateral to the site of stimulation, and (3) an increase in beta-2 band in the middle temporal and inferior parietal lobule on the right side. In the same study (54), brain metabolism using 18FDG-PET was simultaneously measured. While the change of current density of beta bands activities was in accordance with the PET findings, that of delta band was not correlated with brain metabolism (54).
ERPs
Using traditional ERP methods, some authors have investigated the effect of atypical antipsychotic drugs on cognitive function in schizophrenia. As to P50 suppression, treatment with quetiapine of antipsychotic-naïve first-episode patients improved the sensory gating deficits (55). In addition, some atypical antipsychotics, such as clozapine (56, 57) and risperidone (58), showed efficacy for the recovery of P50 suppression.
In treatment studies for the deficits of MMN in schizophrenia, aripiprazole has been reported to increase MMN amplitudes (59). On the other hand, other atypical antipsychotic drugs, such as clozapine (60), risperidone (61), and olanzapine (62) have been shown not to affect MMN amplitudes. Further study on the ability of medication to alleviate altered MMN parameters in the illness is warranted.
In the P300 study, a controlled double-blind trial investigated the effect of clozapine or haloperidol on ERPs, including P300 and MMN, in chronic schizophrenia (60). Treatment with clozapine, but not haloperidol was associated with an increase in P300 amplitudes (60). In another study, clozapine similarly increased P300 amplitudes, and also enhanced performance on working memory tasks (63). On the other hand, the effect of olanzapine on P300 has not been consistent (62, 64–66). Perospirone did not significantly affect P300 in schizophrenia (67).
Using three dimensional images of current density of ERPs in the brain, we reported the ability of treatment with olanzapine for 6 months to enhance P300 current density in the left STG, yielding a distribution pattern of the current density similar to that in healthy control subjects (68). A later study confirmed treatment with olanzapine was associated with increase of P300 current source density in the left STG (69). Importantly, the degree of increase of P300 in the left STG was positively correlated with improvement in negative symptoms and verbal learning memory, while improvement of quality of life was associated with an increase of P300 in the left prefrontal cortex (69). On the other hand, treatment with perospirone was found to improve P300 current density in the left prefrontal cortex, which was related with improvement of daily-living skills, as measured by the script task (70). These findings suggest LORETA imaging of P300 is a useful indicator of treatment response in some aspects of the psychopathology and functional outcomes of schizophrenia.
Clinical Implications
Early intervention into schizophrenia and related conditions has been suggested to improve the prognosis of patients. Accordingly, shorter duration of untreated psychosis has been associated with better long term outcomes (71). Electrophysiological measures may be useful to evaluate the risk for developing psychosis. For example, P300 amplitudes are reduced in the prodromal stage (72, 73). Specifically, treatment with perospirone in an ultra-high risk case immediately before the onset of schizophrenia was shown to “normalize” cognitive function and social outcomes 3 years later. Importantly these neuropsychological and clinical events were preceded by improvement of P300 amplitudes (14). Also, MMN amplitudes have been shown to identify high-risk individuals who later develop overt schizophrenia (44, 74). Taken together, electrophysiological indices may provide a sensitive marker to evaluate treatment effects, including those related to cognitive function, and in some cases, predict the risk of psychosis.
Conclusions
In this review, we have provided a summary of studies relating electrophysiological findings to cognitive performance in schizophrenia. Electrophysiological indices may provide an objective marker of cognitive processes, contributing to the development of effective treatment of cognitive and social outcomes. Further efforts to understand electrophysiological mechanisms of cognitive disturbances, and develop effective therapeutics are warranted.
Author Contributions
All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Part of this work is supported by Intramural Research Grant for Neurological and Psychiatric Disorders of NCNP (29-1, 30-1, 30-8), Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (C) No 17K10321, and AMED under Grant Number 18dk0307081.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1. Keefe RS, Fenton WS. How should DSM-V criteria for schizophrenia include cognitive impairment? Schizophr Bull. (2007) 33:912–20. doi: 10.1093/schbul/sbm046
2. Meltzer HY, Sumiyoshi T. Atypical antipsychotic drugs improve cognition in schizophrenia. Biol Psychiatry (2003) 53:265–7. doi: 10.1016/S0006-3223(02)01790-0
3. Sumiyoshi T, Meltzer H. Pharmacological strategy for enhancement of social function and quality of life in patients with schizophrenia: considerations of the effect of melperone, an atypical antipsychotic drug, on cognitive function. Seishin Igaku (Clinical Psychiatry) (2003) 45:1279–84. doi: 10.11477/mf.1405100748
4. Harvey PD. Pharmacological cognitive enhancement in schizophrenia. Neuropsychol Rev. (2009) 19:324–35. doi: 10.1007/s11065-009-9103-4
5. Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry (2011) 168:472–85. doi: 10.1176/appi.ajp.2010.10060855
6. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, et al. The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. Am J Psychiatry (2008) 165:203–13. doi: 10.1176/appi.ajp.2007.07010042
7. Keefe RSE, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. (2004) 68:283–97. doi: 10.1016/j.schres.2003.09.011
8. Schneider LC, Struening EL. SLOF: a behavioral rating scale for assessing the mentally ill. Soc Work Res Abst. (1983) 19:9–21.
9. Sumiyoshi T, Nishida K, Niimura H, Toyomaki A, Morimoto T, Tani M, et al. Cognitive insight and functional outcome in schizophrenia; a multi-center collaborative study with the specific level of functioning scale-Japanese version. Schizophr Res Cogn. (2016) 6:9–14. doi: 10.1016/j.scog.2016.08.001
10. Sumiyoshi T, Higuchi Y, Uehara T. Neural basis for the ability of atypical antipsychotic drugs to improve cognition in schizophrenia. Front Behav Neurosci. (2013) 7:140. doi: 10.3389/fnbeh.2013.00140
11. Hamilton HK, Williams TJ, Ventura J, Jasperse LJ, Owens EM, Miller GA, et al. Clinical and cognitive significance of auditory sensory processing deficits in schizophrenia. Am J Psychiatry (2018) 175:275–83. doi: 10.1176/appi.ajp.2017.16111203
12. Rissling AJ, Park SH, Young JW, Rissling MB, Sugar CA, Sprock J, et al. Demand and modality of directed attention modulate “pre-attentive” sensory processes in schizophrenia patients and nonpsychiatric controls. Schizophr Res. (2013) 146:326–35. doi: 10.1016/j.schres.2013.01.035
13. Shajahan PM, O'Carroll RE, Glabus MF, Ebmeier KP, Blackwood DHR. Correlation of auditory ‘oddball’ P300 with verbal memory deficits in schizophrenia. Psychol Med. (1997) 27:579–86.
14. Higuchi Y, Sumiyoshi T, Ito T, Suzuki M. Perospirone normalized P300 and cognitive function in a case of early psychosis. J Clin Psychopharmacol. (2013) 33:263–6. doi: 10.1097/JCP.0b013e318287c527
15. Lee SH, Sung K, Lee KS, Moon E, Kim CG. Mismatch negativity is a stronger indicator of functional outcomes than neurocognition or theory of mind in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2014) 48:213–9. doi: 10.1016/j.pnpbp.2013.10.010
16. Pascual-Marqui RD, Lehmann D, Koenig T, Kochi K, Merlo MC, Hell D, et al. Low resolution brain electromagnetic tomography (LORETA) functional imaging in acute, neuroleptic-naive, first-episode, productive schizophrenia. Psychiatry Res. (1999) 90:169–79.
17. Fletcher P, McKenna PJ, Friston KJ, Frith CD, Dolan RJ. Abnormal cingulate modulation of fronto-temporal connectivity in schizophrenia. Neuroimage (1999) 9:337–42. doi: 10.1006/nimg.1998.0411
18. Minzenberg MJ, Laird AR, Thelen S, Carter CS, Glahn DC. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch Gen Psychiatry (2009) 66:811–22. doi: 10.1001/archgenpsychiatry.2009.91
19. Forbes NF, Carrick LA, McIntosh AM, Lawrie SM. Working memory in schizophrenia: a meta-analysis. Psychol Med. (2009) 39:889–905. doi: 10.1017/s0033291708004558
20. Cui Y, Liu B, Song M, Lipnicki DM, Li J, Xie S, et al. Auditory verbal hallucinations are related to cortical thinning in the left middle temporal gyrus of patients with schizophrenia. Psychol Med. (2018) 48:115–22. doi: 10.1017/s0033291717001520
21. Karnath HO. New insights into the functions of the superior temporal cortex. Nat Rev Neurosci. (2001) 2:568–76. doi: 10.1038/35086057
22. Giraud AL, Kell C, Thierfelder C, Sterzer P, Russ MO, Preibisch C, et al. Contributions of sensory input, auditory search and verbal comprehension to cortical activity during speech processing. Cereb Cortex (2004) 14:247–55. doi: 10.1093/cercor/bhg124
23. Buchsbaum MS, Hazlett EA. Positron emission tomography studies of abnormal glucose metabolism in schizophrenia. Schizophr Bull. (1998) 24:343–64. doi: 10.1093/oxfordjournals.schbul.a033331
24. Ragland JD, Yoon J, Minzenberg MJ, Carter CS. Neuroimaging of cognitive disability in schizophrenia: search for a pathophysiological mechanism. Int Rev Psychiatry (2007) 19:417–27. doi: 10.1080/09540260701486365
25. Cocchi L, Harding IH, Lord A, Pantelis C, Yucel M, Zalesky A. Disruption of structure-function coupling in the schizophrenia connectome. Neuroimage Clin. (2014) 4:779–87. doi: 10.1016/j.nicl.2014.05.004
26. Mientus S, Gallinat J, Wuebben Y, Pascual-Marqui RD, Mulert C, Frick K, et al. Cortical hypoactivation during resting EEG in schizophrenics but not in depressives and schizotypal subjects as revealed by low resolution electromagnetic tomography (LORETA). Psychiatry Res. (2002) 116:95–111. doi: 10.1016/S0925-4927(02)00043-4
27. Itoh T, Sumiyoshi T, Higuchi Y, Suzuki M, Kawasaki Y. LORETA analysis of three-dimensional distribution of delta band activity in schizophrenia: relation to negative symptoms. Neurosci Res. (2011) 70:442–8. doi: 10.1016/j.neures.2011.05.003
28. Picton TW, Bentin S, Berg P, Donchin E, Hillyard SA, Johnson R, Jr, et al. Guidelines for using human event-related potentials to study cognition: recording standards and publication criteria. Psychophysiology (2000) 37:127–52. doi: 10.1111/1469-8986.3720127
29. Rissling AJ, Makeig S, Braff DL, Light GA. Neurophysiologic markers of abnormal brain activity in schizophrenia. Curr Psychiatry Rep. (2010) 12:572–8. doi: 10.1007/s11920-010-0149-z
30. Braff DL, Light GA. Preattentional and attentional cognitive deficits as targets for treating schizophrenia. Psychopharmacology (2004) 174:75–85. doi: 10.1007/s00213-004-1848-0
31. Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull. (2007) 33:69–94. doi: 10.1093/schbul/sbl060
32. Braff DL, Geyer MA. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry (1990) 47:181–8.
33. Bramon E, Rabe-Hesketh S, Sham P, Murray RM, Frangou S. Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res. (2004) 70:315–29. doi: 10.1016/j.schres.2004.01.004
34. Erwin RJ, Turetsky BI, Moberg P, Gur RC, Gur RE. P50 abnormalities in schizophrenia: relationship to clinical and neuropsychological indices of attention. Schizophr Res. (1998) 33:157–67.
35. Toyomaki A, Hashimoto N, Kako Y, Tomimatsu Y, Koyama T, Kusumi I. Different P50 sensory gating measures reflect different cognitive dysfunctions in schizophrenia. Schizophr Res Cogn. (2015) 2:166–9. doi: 10.1016/j.scog.2015.07.002
36. Smith AK, Edgar JC, Huang M, Lu BY, Thoma RJ, Hanlon FM, et al. Cognitive abilities and 50- and 100-msec paired-click processes in schizophrenia. Am J Psychiatry (2010) 167:1264–75. doi: 10.1176/appi.ajp.2010.09071059
37. Kawasaki Y, Sumiyoshi T, Higuchi Y, Ito T, Takeuchi M, Kurachi M. Voxel-based analysis of P300 electrophysiological topography associated with positive and negative symptoms of schizophrenia. Schizophr Res. (2007) 94:164–71. doi: 10.1016/j.schres.2007.04.015
38. Umbricht D, Krljes S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res. (2005) 76:1–23. doi: 10.1016/j.schres.2004.12.002
39. Takahashi H, Rissling AJ, Pascual-Marqui R, Kirihara K, Pela M, Sprock J, et al. Neural substrates of normal and impaired preattentive sensory discrimination in large cohorts of nonpsychiatric subjects and schizophrenia patients as indexed by MMN and P3a change detection responses. Neuroimage (2013) 66:594–603. doi: 10.1016/j.neuroimage.2012.09.074
40. Kaur M, Battisti RA, Ward PB, Ahmed A, Hickie IB, Hermens DF. MMN/P3a deficits in first episode psychosis: comparing schizophrenia-spectrum and affective-spectrum subgroups. Schizophr Res. (2011) 130:203–9. doi: 10.1016/j.schres.2011.03.025
41. Hermens DF, Ward PB, Hodge MA, Kaur M, Naismith SL, Hickie IB. Impaired MMN/P3a complex in first-episode psychosis: cognitive and psychosocial associations. Prog Neuropsychopharmacol Biol Psychiatry (2010) 34:822–9. doi: 10.1016/j.pnpbp.2010.03.019
42. Toyomaki A, Kusumi I, Matsuyama T, Kako Y, Ito K, Koyama T. Tone duration mismatch negativity deficits predict impairment of executive function in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2008) 32:95–9. doi: 10.1016/j.pnpbp.2007.07.020
43. Kawakubo Y, Kasai K, Kudo N, Rogers MA, Nakagome K, Itoh K, et al. Phonetic mismatch negativity predicts verbal memory deficits in schizophrenia. Neuroreport (2006) 17:1043–6. doi: 10.1097/01.wnr.0000221828.10846.ba
44. Higuchi Y, Sumiyoshi T, Seo T, Miyanishi T, Kawasaki Y, Suzuki M. Mismatch negativity and cognitive performance for the prediction of psychosis in subjects with at-risk mental state. PLoS ONE (2013) 8:e54080. doi: 10.1371/journal.pone.0054080
45. Friedman T, Sehatpour P, Dias E, Perrin M, Javitt DC. Differential relationships of mismatch negativity and visual p1 deficits to premorbid characteristics and functional outcome in schizophrenia. Biol Psychiatry (2012) 71:521–9. doi: 10.1016/j.biopsych.2011.10.037
46. Kawakubo Y, Kasai K. Support for an association between mismatch negativity and social functioning in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2006) 30:1367–8. doi: 10.1016/j.pnpbp.2006.03.003
47. Light GA, Braff DL. Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch Gen Psychiatry (2005) 62:127–36. doi: 10.1001/archpsyc.62.2.127
48. Frank DW, Yee RB, Polich J. P3a from white noise. Int J Psychophysiol. (2012) 85:236–41. doi: 10.1016/j.ijpsycho.2012.04.005
49. Nieman DH, Koelman JH, Linszen DH, Bour LJ, Dingemans PM, Ongerboer de Visser BW. Clinical and neuropsychological correlates of the P300 in schizophrenia. Schizophr Res. (2002) 55:105–13. doi: 10.1016/S0920-9964(01)00184-0
50. Heidrich A, Strik WK. Auditory P300 topography and neuropsychological test performance: evidence for left hemispheric dysfunction in schizophrenia. Biol Psychiatry (1997) 41:327–35. doi: 10.1016/S0006-3223(96)00030-3
51. Souza VB, Muir WJ, Walker MT, Glabus MF, Roxborough HM, Sharp CW, et al. Auditory P300 event-related potentials and neuropsychological performance in schizophrenia and bipolar affective disorder. Biol Psychiatry (1995) 37:300–10. doi: 10.1016/0006-3223(94)00131-l
52. Higuchi Y, Sumiyoshi T, Seo T, Suga M, Takahashi T, Nishiyama S, et al. Associations between daily living skills, cognition, and real-world functioning across stages of schizophrenia; a study with the schizophrenia cognition rating scale japanese version. Schizophr Res Cogn. (2017) 7:13–8. doi: 10.1016/j.scog.2017.01.001
53. Turetsky BI, Dress EM, Braff DL, Calkins ME, Green MF, Greenwood TA, et al. The utility of P300 as a schizophrenia endophenotype and predictive biomarker: clinical and socio-demographic modulators in COGS-2. Schizophr Res. (2015) 163:53–62. doi: 10.1016/j.schres.2014.09.024
54. Horacek J, Brunovsky M, Novak T, Skrdlantova L, Klirova M, Bubenikova-Valesova V, et al. Effect of low-frequency rTMS on electromagnetic tomography (LORETA) and regional brain metabolism (PET) in schizophrenia patients with auditory hallucinations. Neuropsychobiology (2007) 55:132–42. doi: 10.1159/000106055
55. Oranje B, Aggernaes B, Rasmussen H, Ebdrup BH, Glenthoj BY. P50 suppression and its neural generators in antipsychotic-naive first-episode schizophrenia before and after 6 months of quetiapine treatment. Schizophr Bull. (2013) 39:472–80. doi: 10.1093/schbul/sbr183
56. Nagamoto HT, Adler LE, Hea RA, Griffith JM, McRae KA, Freedman R. Gating of auditory P50 in schizophrenics: unique effects of clozapine. Biol Psychiatry (1996) 40:181–8. doi: 10.1016/0006-3223(95)00371-1
57. Adler LE, Olincy A, Cawthra EM, McRae KA, Harris JG, Nagamoto HT, et al. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. Am J Psychiatry (2004) 161:1822–8. doi: 10.1176/ajp.161.10.1822
58. Yee CM, Nuechterlein KH, Morris SE, White PM. P50 suppression in recent-onset schizophrenia: clinical correlates and risperidone effects. J Abnorm Psychol (1998) 107:691–8.
59. Zhou Z, Zhu H, Chen L. Effect of aripiprazole on mismatch negativity (MMN) in schizophrenia. PLoS ONE (2013) 8:e52186. doi: 10.1371/journal.pone.0052186
60. Umbricht D, Javitt D, Novak G, Bates J, Pollack S, Lieberman J, et al. Effects of clozapine on auditory event-related potentials in schizophrenia. Biol Psychiatry (1998) 44:716–25.
61. Umbricht D, Javitt D, Novak G, Bates J, Pollack S, Lieberman J, et al. Effects of risperidone on auditory event-related potentials in schizophrenia. Int J Neuropsychopharmacol. (1999) 2:299–304. doi: 10.1017/s1461145799001595
62. Korostenskaja M, Dapsys K, Siurkute A, Maciulis V, Ruksenas O, Kahkonen S. Effects of olanzapine on auditory P300 and mismatch negativity (MMN) in schizophrenia spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry (2005) 29:543–8. doi: 10.1016/j.pnpbp.2005.01.019
63. Galletly CA, Clark CR, McFarlane AC. Clozapine improves working memory updating in schizophrenia. Eur Neuropsychopharmacol. (2005) 15:601–8. doi: 10.1016/j.euroneuro.2005.03.001
64. Gallinat J, Riedel M, Juckel G, Sokullu S, Frodl T, Moukhtieva R, et al. P300 and symptom improvement in schizophrenia. Psychopharmacology (2001) 158:55–65. doi: 10.1007/s002130100835
65. Gonul AS, Suer C, Coburn K, Ozesmi C, Oguz A, Yilmaz A. Effects of olanzapine on auditory P300 in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2003) 27:173–7. doi: 10.1016/S0278-5846(02)00349-4
66. Molina V, Munoz F, Martin-Loeches M, Casado P, Hinojosa JA, Iglesias A. Long-term olanzapine treatment and p300 parameters in schizophrenia. Neuropsychobiology (2004) 50:182–8. doi: 10.1159/000079112
67. Araki T, Kasai K, Rogers MA, Kato N, Iwanami A. The effect of perospirone on auditory P300 in schizophrenia: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry (2006) 30:1083–90. doi: 10.1016/j.pnpbp.2006.04.009
68. Sumiyoshi T, Higuchi Y, Kawasaki Y, Matsui M, Kato K, Yuuki H, et al. Electrical brain activity and response to olanzapine in schizophrenia: a study with LORETA images of P300. Prog Neuropsychopharmacol Biol Psychiatry (2006) 30:1299–303. doi: 10.1016/j.pnpbp.2006.04.028
69. Higuchi Y, Sumiyoshi T, Kawasaki Y, Matsui M, Arai H, Kurachi M. Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: a LORETA analysis of P300. Schizophr Res. (2008) 101:320–30. doi: 10.1016/j.schres.2008.01.020
70. Sumiyoshi T, Higuchi Y, Itoh T, Matsui M, Arai H, Suzuki M, et al. Effect of perospirone on P300 electrophysiological activity and social cognition in schizophrenia: a three-dimensional analysis with sloreta. Psychiatry Res. (2009) 172:180–3. doi: 10.1016/j.pscychresns.2008.07.005
71. Woods SW, McGlashan TH, Walsh BC. The Psychosis-Risk Syndrome Handbook for Diagnosis and Follow-Up. New York, NY: Oxford University Press (2010).
72. Ozgurdal S, Gudlowski Y, Witthaus H, Kawohl W, Uhl I, Hauser M, et al. Reduction of auditory event-related P300 amplitude in subjects with at-risk mental state for schizophrenia. Schizophr Res. (2008) 105:272–8. doi: 10.1016/j.schres.2008.05.017
73. Frommann I, Brinkmeyer J, Ruhrmann S, Hack E, Brockhaus-Dumke A, Bechdolf A, et al. Auditory P300 in individuals clinically at risk for psychosis. Int J Psychophysiol. (2008) 70:192–205. doi: 10.1016/j.ijpsycho.2008.07.003
Keywords: electroencephalogram, event related potentials, LORETA, cognition, schizophrenia
Citation: Sueyoshi K and Sumiyoshi T (2018) Electrophysiological Evidence in Schizophrenia in Relation to Treatment Response. Front. Psychiatry 9:259. doi: 10.3389/fpsyt.2018.00259
Received: 11 January 2018; Accepted: 25 May 2018;
Published: 13 June 2018.
Edited by:
Roumen Kirov, Institute of Neurobiology (BAS), BulgariaReviewed by:
Kesong Hu, DePauw University, United StatesAtsuhito Toyomaki, Hokkaido University, Japan
Copyright © 2018 Sueyoshi and Sumiyoshi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Tomiki Sumiyoshi, c3VtaXlvdEBuY25wLmdvLmpw